Skip to main content

Research Repository

Advanced Search

All Outputs (4)

Detection of nephrocalcinosis using ultrasonography, micro-computed tomography, and histopathology in cats (2024)
Journal Article
Tang, P., Geddes, R., Chang, Y., Jepson, R., van den Broek, D., Lötter, N., & Elliott, J. (2024). Detection of nephrocalcinosis using ultrasonography, micro-computed tomography, and histopathology in cats. Journal of Veterinary Internal Medicine, https://doi.org/10.1111/jvim.17011

BackgroundIdentification of nephrocalcinosis in cats with chronic kidney disease (CKD) is of clinical interest but the ability of ultrasonography to detect nephrocalcinosis is uncertain.ObjectivesTo compare ultrasonography, micro-computed tomography... Read More about Detection of nephrocalcinosis using ultrasonography, micro-computed tomography, and histopathology in cats.

The effect of myxomatous mitral valve disease severity on packed cell volume in dogs (2021)
Journal Article
Wilshaw, J., Stein, M., Lotter, N., Elliott, J., & Boswood, A. (2021). The effect of myxomatous mitral valve disease severity on packed cell volume in dogs. Journal of Small Animal Practice, 62(6), 428-436. https://doi.org/10.1111/jsap.13308

Objectives The aim of this study was to examine whether associations between disease severity and packed cell volume exist in dogs with myxomatous mitral valve disease. Materials and Methods Data were selected from 289 dogs that had been examined at... Read More about The effect of myxomatous mitral valve disease severity on packed cell volume in dogs.

Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study (2017)
Journal Article
Hezzell, M. J., Boswood, A., Lopez-Alvarez, J., Lotter, N. S., & Elliott, J. (2017). Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study. Journal of Veterinary Cardiology, 19(4), 325-328. https://doi.org/10.1016/j.jvc.2017.06.001

Spironolactone improves outcome in dogs with advanced myxomatous mitral valve disease (MMVD). Its efficacy in preclinical MMVD is unknown. The hypothesis was the administration of spironolactone to dogs with compensated MMVD demonstrating risk factor... Read More about Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone-a pilot study.